Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics

被引:6
|
作者
Ngo, Lien [1 ]
Yoo, Hee-Doo [1 ]
Tran, Phuong [1 ]
Cho, Hea-Young [2 ]
Lee, Yong-Bok [1 ]
机构
[1] Chonnam Natl Univ, Inst Bioequivalence & Bridging Study, Coll Pharm, 77 Yongbong Ro, Gwangju 61186, South Korea
[2] CHA Univ, Coll Pharm, 335 Pangyo Ro, Seongnam Si 13488, Gyeonggido, South Korea
基金
新加坡国家研究基金会;
关键词
Rebamipide; Population; Pharmacokinetics; Genetic polymorphism; MDR1; MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN EXPRESSION; ORAL BIOAVAILABILITY; HELICOBACTER-PYLORI; ANTIULCER AGENT; SOLID DISPERSION; MALE-VOLUNTEERS; MDR1; GENE; POLYMORPHISMS; DRUG;
D O I
10.1007/s10928-017-9519-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this study, the population pharmacokinetic (PK) analysis of rebamipide (Reba) in healthy male Korean subjects was analyzed using the nonlinear mixed effects modeling method. The possible effects of physiological covariates and the multidrug resistance (MDR1) gene 3435C > T polymorphism on PK parameters were also investigated. Data were collected from a bioequivalence study, in which 26 subjects who participated in the study were administered a single oral dose of 100 mg Reba; only data from the reference formulation were used. Reba showed a relatively large inter-individual variability (from 2.6- to 3.3-fold) in the PK parameters with double peaks or the concentration plateau after the peak concentration in its serum concentration-time profiles. The population PKs of Reba was best described by a one-compartment model with three fraction absorption processes followed a single Weibull-type function and two first-order kinetics, and lag times. The study suggests that the efflux transporter MDR1 3435C > T allele affects the substantial inter-individual variability in the absorption of Reba according to genetic polymorphism. A significant difference was found in the absorption rate ka (1) among the MDR1 3435C > T genotype groups (P < 0.05) (CT group, 79.8% increase; and TT group, 115% increase). The use of combined MDR1 3435C > T and body mass index as covariates for ka (1) exerted a more significant effect (P < 0.05). In addition, body surface area significantly affected the apparent total clearance (P < 0.05).
引用
下载
收藏
页码:291 / 303
页数:13
相关论文
共 50 条
  • [31] Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese
    Choi, Yewon
    Yoon, Seonghae
    Matsumoto, Kyoko
    Ohta, Yoshiyasu
    Lee, Seunghwan
    Yu, Kyung-Sang
    Jang, In-Jin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1045 - 1051
  • [32] Population pharmacokinetic analysis of febuxostat with high focus on absorption kinetics and food effect
    Chen, Wenjun
    Jiang, Bo
    Ruan, Zourong
    Yang, Dandan
    Hu, Yin
    Lou, Honggang
    BMC PHARMACOLOGY & TOXICOLOGY, 2024, 25 (01):
  • [33] Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus
    Kun Wang
    Lingge Feng
    Jiayi Zhang
    Quanfei Zou
    Fengyan Xu
    Zhongyi Sun
    Fuxing Tang
    Li Chen
    Clinical Pharmacokinetics, 2023, 62 : 1413 - 1425
  • [34] Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus
    Wang, Kun
    Feng, Lingge
    Zhang, Jiayi
    Zou, Quanfei
    Xu, Fengyan
    Sun, Zhongyi
    Tang, Fuxing
    Chen, Li
    CLINICAL PHARMACOKINETICS, 2023, 62 (10) : 1413 - 1425
  • [35] Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects
    Mario González-Sales
    Olivier Barrière
    Pierre Olivier Tremblay
    Fahima Nekka
    Jean-Claude Mamputu
    Sylvie Boudreault
    Mario Tanguay
    Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42 : 287 - 299
  • [36] Population pharmacokinetic analysis of clopidogrel in healthy Jordanian subjects with emphasis optimal sampling strategy
    Yousef, A. M.
    Melhem, M.
    Xue, B.
    Arafat, T.
    Reynolds, D. K.
    Van Wart, S. A.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (04) : 215 - 226
  • [37] Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects
    Gonzalez-Sales, Mario
    Barriere, Olivier
    Tremblay, Pierre Olivier
    Nekka, Fahima
    Mamputu, Jean-Claude
    Boudreault, Sylvie
    Tanguay, Mario
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 (03) : 287 - 299
  • [38] POPULATION PHARMACOKINETIC ANALYSIS OF SPARSENTAN IN HEALTHY VOLUNTEERS AND SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS).
    Chen, S.
    Wada, R.
    Zhang, L.
    Kleijn, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S14 - S14
  • [39] Population pharmacokinetic analysis of dapagliflozin in healthy and subjects with type 2 diabetes mellitus.
    Feng, Y.
    Zhang, L.
    Komoroski, B.
    Pfister, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S93 - S93
  • [40] Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout
    Kamel, Bishoy
    Abuhelwa, Ahmad Y.
    Foster, David
    Duong, Janna K.
    Graham, Garry G.
    Williams, Kenneth M.
    Pile, Kevin D.
    Day, Richard O.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (12) : 5359 - 5368